# FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR

> **NCT00810030** · PHASE3 · COMPLETED · sponsor: **Vifor Pharma** · enrollment: 484 (actual)

## Conditions studied

- Inflammatory Bowel Disease
- Anemia
- Iron Deficiency
- Iron-Deficiency Anemia
- Crohn's Disease
- Ulcerative Colitis

## Interventions

- **DRUG:** Ferric carboxymaltose
- **DRUG:** Iron Sucrose

## Key facts

- **NCT ID:** NCT00810030
- **Lead sponsor:** Vifor Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-12
- **Final completion:** 2010-04
- **Target enrollment:** 484 (ACTUAL)
- **Last updated:** 2012-12-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00810030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00810030, "FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00810030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*